| __timestamp | Alkermes plc | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 199905000 | 35942000 |
| Thursday, January 1, 2015 | 311558000 | 40028000 |
| Friday, January 1, 2016 | 374130000 | 45853000 |
| Sunday, January 1, 2017 | 421578000 | 53816000 |
| Monday, January 1, 2018 | 526408000 | 60804000 |
| Tuesday, January 1, 2019 | 599449000 | 77252000 |
| Wednesday, January 1, 2020 | 538827000 | 45736000 |
| Friday, January 1, 2021 | 560977000 | 50323000 |
| Saturday, January 1, 2022 | 605747000 | 143526000 |
| Sunday, January 1, 2023 | 689751000 | 149182000 |
| Monday, January 1, 2024 | 645238000 | 154335000 |
Unleashing the power of data
In the competitive world of biopharmaceuticals, managing operational costs is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Halozyme Therapeutics, Inc. and Alkermes plc from 2014 to 2023. Over this period, Alkermes consistently outspent Halozyme, with its SG&A expenses peaking at approximately $690 million in 2023, a 245% increase from 2014. In contrast, Halozyme's expenses grew by over 300%, reaching nearly $150 million in 2023. This trend highlights Alkermes' larger scale and operational complexity, while Halozyme's rapid growth reflects its expanding market presence. Understanding these financial dynamics offers insights into each company's strategic priorities and market positioning.
Breaking Down SG&A Expenses: Johnson & Johnson vs Alkermes plc
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Alkermes plc
Sarepta Therapeutics, Inc. or Halozyme Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Grifols, S.A.
SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Verona Pharma plc
Halozyme Therapeutics, Inc. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or MannKind Corporation
SG&A Efficiency Analysis: Comparing Cytokinetics, Incorporated and Alkermes plc
Comparing SG&A Expenses: Alkermes plc vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: Alkermes plc vs Evotec SE Trends and Insights